Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-DF vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and blocking adenosine receptors.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/m L.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4; first-pass metabolism; ~90% metabolized, <10% excreted unchanged.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to plasma proteins, primarily albumin.
65% bound to albumin
Apparent volume of distribution: 0.45 L/kg; distributes freely into body water, with higher distribution in neonates and patients with liver disease.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 96–100%; oral extended-release (Somophyllin-DF): 80–100% relative to intravenous, with reduced absorption due to slower release.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No dose adjustment required for renal impairment. However, monitor serum levels in patients with renal failure receiving theophylline as metabolites may accumulate.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B: Reduce dose by 60-75%. Child-Pugh Class C: Reduce dose by 80-90%. Monitor serum levels closely.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Oral: Initial 16 mg/kg/day or 400 mg/day (whichever is less) in divided doses every 12 hours; extended-release. Adjust based on serum levels. Maximum 20 mg/kg/day or 800 mg/day.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients: Start at lower end of dosing range, 300-400 mg/day in divided doses. Monitor serum levels frequently due to decreased clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
Cardiovascular toxicity (arrhythmias), seizure risk, hypersensitivity reactions, interactions with fluoroquinolones and macrolides, smoking cessation reduces clearance, monitor serum theophylline levels.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or xanthines, active peptic ulcer disease, uncontrolled seizure disorders.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate, energy drinks) as it can increase stimulant effects and risk of toxicity. Charcoal-broiled foods may increase metabolism of theophylline, potentially reducing effectiveness. High-protein/low-carbohydrate diets may reduce clearance; high-carbohydrate/low-protein diets may increase clearance. Grapefruit juice does not significantly interact, but consistent intake pattern is advised.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Theophylline (SOMOPHYLLIN-DF) is not a major human teratogen. First trimester: Retrospective studies show no significant increase in congenital anomalies, but data are limited. Second/third trimester: Fetal tachycardia, irritability, and jitteriness can occur due to transplacental passage; risk of neonatal withdrawal if used near term. Avoid high doses near delivery.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with a milk-to-plasma ratio approximately 0.67. Infant serum levels can reach therapeutic or toxic concentrations, especially in preterm or neonatal infants. Caution advised; monitor infant for irritability or poor feeding. Use only if clearly needed.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Clearance of theophylline decreases in the third trimester due to reduced hepatic metabolism. Doses may need reduction by 20-30% compared to non-pregnant state, guided by trough serum concentrations. Increase monitoring frequency (every 1-2 weeks) during dose adjustments.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Verify controlled-release properties: do not crush or chew tablets. Monitor theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Use with caution in patients with CHF, hepatic impairment, or febrile illness as clearance may decrease. Cigarette smoking increases clearance; adjust dose accordingly. Concurrent use with cimetidine, fluoroquinolones, or macrolides can significantly increase levels.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not skip doses or double up. Swallow tablets whole—do not crush or chew. Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects. Report symptoms of toxicity: persistent nausea, vomiting, insomnia, jitteriness, or rapid heart rate. Do not smoke or stop smoking without telling your doctor; smoking changes how this medicine works. Keep all appointments for blood tests to check drug levels. Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-DF vs AEROLATE, answered by our medical review team.
SOMOPHYLLIN-DF is a Bronchodilator that works by Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and blocking adenosine receptors.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-DF and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-DF is: Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-DF and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-DF is classified as Category C. Theophylline (SOMOPHYLLIN-DF) is not a major human teratogen. First trimester: Retrospective studies show no significant increase in congenital anomalies, but data are limited. Sec. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.